Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Should You Buy?
11:01am, Wednesday, 09'th Jul 2025
Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term
10:41am, Wednesday, 09'th Jul 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?
10:15am, Wednesday, 09'th Jul 2025
JNJ's growth outlook, rising estimates, and strength in Innovative Medicine give it an edge over Pfizer in 2025.
Johnson & Johnson: What To Expect From The Upcoming Q2 Earnings?
10:02am, Wednesday, 09'th Jul 2025
JNJ which has outperformed the S&P 500 and other large-cap healthcare peers in H1-2025, now faces a crucial test with Q2 results due to be announced on the 16th ofJuly. JNJ has a long history of beati
Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'
01:41pm, Tuesday, 08'th Jul 2025
President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. "very soon." But he suggested that those levies would not go into effect immediately, saying
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
10:41am, Tuesday, 08'th Jul 2025
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
Dogs of the Dow: These Are The Best Dividend Stocks in July 2025
10:10am, Tuesday, 08'th Jul 2025
If you're keen on following the Dogs of the Dow investing strategy, here are three stocks with a high-yield.
Submission is based on long-term Phase 3 data demonstrating 63 percent reduction in risk of relapse in adults with schizophrenia compared to placebo CAPLYTA® is FDA approved to treat schizophrenia an
NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)
04:15pm, Monday, 07'th Jul 2025
PARIS and CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-
3 Must-Buy Dividend Stocks if You Only Have $5,000 to Spend
11:18am, Monday, 07'th Jul 2025
The vast majority of investors don't have hundreds of thousands to bet on each stock.
Here's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock
10:55am, Monday, 07'th Jul 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Will J&J's Q2 Results Reflect End of MedTech Issues & Higher Sales?
10:31am, Monday, 07'th Jul 2025
JNJ's MedTech unit eyes second-half growth despite China headwinds, U.S. competition and tariff pressure.
Should You Forget Johnson & Johnson and Buy This Magnificent High-Yield Dividend Stock Instead?
06:07am, Monday, 07'th Jul 2025
Johnson & Johnson (JNJ 0.29%) is a storied company that has an incredible track record of returning value to investors over time via dividend increases. And the yield is attractive today at 3.4%.
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 9% (July 2025)
08:00am, Saturday, 05'th Jul 2025
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:56am, Friday, 04'th Jul 2025
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
